Mirum Pharmaceuticals agreed to acquire Bluejay Therapeutics in a cash‑and‑stock deal to add brelovitug, a late‑stage monoclonal antibody for chronic hepatitis D virus (HDV), to its rare‑liver disease portfolio. The transaction structures include an upfront component and additional equity and milestone payments, according to company announcements and industry reports. Brelovitug holds Breakthrough Therapy and PRIME designations and is being evaluated in the global AZURE Phase III registrational program with topline readouts expected in H2 2026. Mirum said the asset complements its existing liver programs (volixibat, LIVMARLI) and accelerates its rare‑disease strategy by adding an antiviral candidate with strong Phase II activity. Deal terms and integration plans highlight Mirum’s push to scale a rare‑liver franchise ahead of potential BLA submissions; investors and analysts will monitor enrollment, Phase III pharmacodynamics and regulatory interactions in the coming quarters.